Muscarinic Acetylcholine Receptor M4 (CHRM4) – Drugs In Development, 2021

Muscarinic Acetylcholine Receptor M4 (CHRM4) – Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 17 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 9 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Ophthalmology and Undisclosed which include indications Schizophrenia, Alzheimer's Disease, Psychosis, Parkinson's Disease, Angelman Syndrome, Cognitive Impairment Associated With Schizophrenia (CIAS), Drug-Induced Dyskinesia, Fragile X Syndrome, Infantile Spasm (West Syndrome), Neurology, Presbyopia, Rett Syndrome, Tuberous Sclerosis, Unspecified Neurologic Disorders and Unspecified Rare Disease.

The latest report Muscarinic Acetylcholine Receptor M4 – Drugs In Development, 2021, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

– The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

– The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4) Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Anavex Life Sciences Corp

AstraZeneca Plc

Karuna Therapeutics Inc

Lan Sheng Biomedicine Suzhou Co Ltd

Lenz Therapeutics LLC

NeuroSolis Inc

Sosei Heptares

Suven Life Sciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

AstraZeneca Plc

Karuna Therapeutics Inc

Lan Sheng Biomedicine Suzhou Co Ltd

Lenz Therapeutics LLC

NeuroSolis Inc

Sosei Heptares

Suven Life Sciences Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles

(aceclidine + tropicamide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blarcamesine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVL-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize CHRM4 for Drug-Induced Dyskinesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0016878 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LS-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527f - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559f - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Muscarinic Acetylcholine Receptor M4 for Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Unspecified Neurologic Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-6000918 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-6001852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones

Featured News & Press Releases

Jun 23, 2021: Karuna Therapeutics announces results from phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers

Jun 21, 2021: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) biomarker correlated with efficacy endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome

Jun 14, 2021: Anavex Life Sciences reports new publication in medical journal elucidating the mechanism of ANAVEX2-73 (blarcamesine) related to the treatment of Alzheimer's Disease

Jun 08, 2021: Anavex Life Sciences announces exceeding of enrollment target for the precision medicine ANAVEX2-73 (blarcamesine) phase 2b/3 clinical trial in patients with Alzheimer’s Disease

Jun 03, 2021: Anavex Life Sciences announces Notice of allowance for U.S. patent application ANAVEX2-73 (blarcamesine) for the treatment of cardiac dysfunctions

Apr 12, 2021: Anavex Life Sciences reports the results of review by the Independent Data Safety Monitoring Board for its phase 2/3 trials of ANAVEX2-73 in patients with Rett syndrome

Mar 31, 2021: Anavex Life Sciences reports data review by the Independent Data Safety Monitoring board for its phase 2b/3 clinical trial of ANAVEX2-73 in patients with Alzheimer’s Disease

Mar 16, 2021: Anavex Life Sciences reports ANAVEX2-73 (blarcamesine) featured as a disease-modifying small molecule in phase 3 clinical trials in a new publication in medical journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”

Feb 24, 2021: Karuna Therapeutics anounces New England Journal of Medicine publication of data from EMERGENT-1 phase 2 trial evaluating KarXT in Schizophrenia

Jan 11, 2021: Anavex Life Sciences receives Michael J. Fox Foundation grant for clinical study of ANAVEX2-73 (blarcamesine) in people with Parkinson’s Disease

Dec 21, 2020: Anavex Life Sciences announces webinar on Rett syndrome and ANAVEX2-73 (Blarcamesine) phase 2 data hosted by Ladenburg Thalmann & Co.

Dec 15, 2020: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) meets primary and secondary endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome

Nov 30, 2020: Anavex Life Sciences announces notice of allowance for U.S. Patent Application with expanding claims covering ANAVEX2-73 (blarcamesine) for the treatment of Rett Syndrome and other neurodevelopmental disorders

Nov 06, 2020: Proof of concept controlled phase 2 clinical trial data evaluating ANAVEX2-73 (blarcamesine) in Parkinson’s disease dementia presented at CTAD 2020 conference

Oct 15, 2020: Anavex Life Sciences announces positive results from proof of concept controlled phase 2 clinical trial evaluating Anavex 2-73 (blarcamesine) in Parkinson’s disease dementia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Anavex Life Sciences Corp, 2021

Pipeline by AstraZeneca Plc, 2021

Pipeline by Karuna Therapeutics Inc, 2021

Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, 2021

Pipeline by Lenz Therapeutics LLC, 2021

Pipeline by NeuroSolis Inc, 2021

Pipeline by Sosei Heptares, 2021

Pipeline by Suven Life Sciences Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports